Design and Mechanism of Action of a New Prototype of Combi-Molecule “Programed” to Release Bioactive Species at a pH Range Akin to That of the Tumor Microenvironment

Design and Mechanism of Action of a New Prototype of Combi-Molecule “Programed” to Release Bioactive Species at a pH Range Akin to That of the Tumor Microenvironment

The clinical use of cytotoxic agents is plagued by systemic toxicity. We report a novel approach that seeks to design a “combi-molecule” to behave as an alkylating agent on its own and to undergo acid-catalyzed conversion to two bioactive species at a pH range akin to that of a tumor microenvironmen...

Bibliografiset tiedot
Päätekijät:	Anne-Laure Larroque-Lombard, Etienne Chatelut, Jean-Pierre Delord, Diane-Charlotte Imbs, Philippe Rochaix, Bertrand Jean-Claude, Ben Allal
Aineistotyyppi:	Artikkeli
Kieli:	English
Julkaistu:	MDPI AG 2021-02-01
Sarja:	Pharmaceuticals
Aiheet:	combi-molecules MEK synergy microenvironment pharmacokinetics
Linkit:	https://www.mdpi.com/1424-8247/14/2/160

Samankaltaisia teoksia

Persistent microfilaricidal effect of aversect combi at onchocercosis and setariosis in cattle
Tekijä: I. A. Arkhipov, et al.
Julkaistu: (2016-05-01)

ASSESSMENT OF EFFECTS OF DRUGS AVERSECT FORTE AND AVERSECT COMBI ON EMBRYONIC DEVELOPMENT OF THE RAT
Tekijä: M. V. Semenova, et al.
Julkaistu: (2016-12-01)

THE STUDY OF IMMUNOTOXIC PROPERTIES OF AVERSECT FORTE AND AVERSECT COMBI
Tekijä: M. V. Semenova, et al.
Julkaistu: (2016-05-01)

A descriptive summary of the WHO availability assessments of medical abortion medicines in eight African countries
Tekijä: Amy Grossman, et al.
Julkaistu: (2024-12-01)

Lupeol: triterpene from Iraqi Portulaca grandiflora L (Portulacaceae): Its Extraction, identification (GC/MS), Isolation(Combiflash), and Structure Elucidation.
Tekijä: Hadeel Kareem Mus’hib, et al.
Julkaistu: (2025-02-01)

Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany
Tekijä: S Wahler, et al.
Julkaistu: (2021-01-01)

Mediatieve behandeling bij mensen met zowel neuro-cognitieve stoornissen als persoonlijkheids-problematiek
Tekijä: Erol Ekiz, et al.
Julkaistu: (2020-05-01)

Definition of the Neurotoxicity-Associated Metabolic Signature Triggered by Berberine and Other Respiratory Chain Inhibitors
Tekijä: Ilinca Suciu, et al.
Julkaistu: (2023-12-01)

Corrigendum: Co-treatment of chloroquine and trametinib inhibits melanoma cell proliferation and decreases immune cell infiltration
Tekijä: Simone Degan, et al.
Julkaistu: (2024-04-01)

Exploring the inhibitory potential of xanthohumol on MEK1/2: a molecular docking and dynamics simulation investigation
Tekijä: Zohreh Gholizadeh Siahmazgi, et al.
Julkaistu: (2024-12-01)

Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors
Tekijä: Lena Hummel, et al.
Julkaistu: (2024-05-01)

Effective therapy of hypertension from the standpoint of patient-centered medicine
Tekijä: V. I. Podzolkov, et al.
Julkaistu: (2023-05-01)

Limited Sampling Strategy for Determination of Ibrutinib Plasma Exposure: Joint Analyses with Metabolite Data
Tekijä: Félicien Le Louedec, et al.
Julkaistu: (2021-02-01)

Novel therapy: Combined BRAF and MEK inhibitors for locally advanced BRAF V600L–Positive mucosal melanoma in hypopharynx
Tekijä: Sivakamavalli Jeyachandran
Julkaistu: (2024-06-01)

Biopharmaceutical profiling of anti-infective sanggenons from Morus alba root bark for inhalation administration
Tekijä: Jacqueline Schwarzinger, et al.
Julkaistu: (2024-12-01)

Streptolysin O Deficiency in Streptococcus pyogenes M1T1 covR/S Mutant Strain Attenuates Virulence in In Vitro and In Vivo Infection Models
Tekijä: Emma L. Langshaw, et al.
Julkaistu: (2023-02-01)

Effect of Different Cooking Methods on the Aroma and Taste of Chicken Broth
Tekijä: Can Yuan, et al.
Julkaistu: (2024-03-01)

Akin Afar
Tekijä: Lau, Yi Wen
Julkaistu: (2019)

MAP kinase kinase 1 (MEK1) within extracellular vesicles inhibits tumour growth by promoting anti‐tumour immunity
Tekijä: Stephen C. Searles, et al.
Julkaistu: (2024-10-01)

Targeting the RAS pathway by mitogen-activated protein kinase inhibitors
Tekijä: Michael Kiessling, et al.
Julkaistu: (2015-12-01)

Dual inhibition of SUMOylation and MEK conquers MYC-expressing KRAS-mutant cancers by accumulating DNA damage
Tekijä: Hiroshi Kotani, et al.
Julkaistu: (2024-07-01)

Adjuvant treatments in melanoma
Tekijä: Luka Simetić, et al.
Julkaistu: (2021-01-01)

KRAS is a molecular determinant of platinum responsiveness in glioblastoma
Tekijä: Candida Zuchegna, et al.
Julkaistu: (2024-01-01)

NGF activates NFAT via the MEK1/2 pathway in PC12 cells
Tekijä: Man Su Kim
Julkaistu: (2022-12-01)

<i>Zingiber officinale</i> Uncovered: Integrating Experimental and Computational Approaches to Antibacterial and Phytochemical Profiling
Tekijä: Abdel Moneim Elhadi Sulieman, et al.
Julkaistu: (2024-11-01)

An introduction to the theory of molecular structure/
Tekijä: 211799 Charette, Jean-Joseph
Julkaistu: (1966)

Untangling sporadic brain arteriovenous malformations: towards targeting the KRAS/MAPK pathway
Tekijä: Rashad Jabarkheel, et al.
Julkaistu: (2024-12-01)

Rosavin exerts an antitumor role and inactivates the MAPK/ERK pathway in small-cell lung carcinoma in vitro
Tekijä: Liu Rui, et al.
Julkaistu: (2023-06-01)

Pin1–FOXM1 inhibitors: a potential therapeutic for metastatic melanoma?
Tekijä: Peter LJ de Keizer
Julkaistu: (2016-09-01)

Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib
Tekijä: Andrea Gazzin, et al.
Julkaistu: (2024-06-01)

Domperidone inhibits cell proliferation via targeting MEK and CDK4 in esophageal squamous cell carcinoma
Tekijä: Qiang Yuan, et al.
Julkaistu: (2024-03-01)

Efficiency of B-RAF-/MEK-inhibitors in B-RAF mutated Ameloblastoma: Case report and review of literature
Tekijä: Reinhard Büttner, et al.
Julkaistu: (2023-12-01)

Successful treatment of MAP2K1 mutant stage IV-M1d melanoma with trametinib plus low-dose dabrafenib: a case report
Tekijä: Iris Dirven, et al.
Julkaistu: (2024-09-01)

Liprin‐α1 contributes to oncogenic MAPK signaling by counteracting ERK activity
Tekijä: Henna Pehkonen, et al.
Julkaistu: (2024-03-01)

Transferring Sensor-Based Assessments to Clinical Practice: The Case of Muscle Synergies
Tekijä: Alessandro Scano, et al.
Julkaistu: (2024-06-01)

Pharmacokinetic modelling using Stella on the Apple Macintosh /
Tekijä: 264867 Washington, Clive, et al.
Julkaistu: (1990)

SYNERGY OF THE ENTERPRISE'S PERSONNEL AS A SOURCE OF ACHIEVING COMPETITITVE ADVANTAGES
Tekijä: E. B. Saifutdinova
Julkaistu: (2011-09-01)

Tetrandrine sensitizes nasopharyngeal carcinoma cells to irradiation by inducing autophagy and inhibiting MEK/ERK pathway
Tekijä: Jun Wang, et al.
Julkaistu: (2020-10-01)

Practical application of precision oncology in adult onset craniopharyngiomas
Tekijä: Chandrima Biswas, et al.
Julkaistu: (2024-11-01)

Treatment with BRAF/MEK: inhibitors in mutant BRAF V600E papillary craniopharyngioma
Tekijä: Eva Marie Erfurth, et al.
Julkaistu: (2024-12-01)